FIELD: chemistry.
SUBSTANCE: invention relates to biotechnology, genetic engineering and virology. The structure includes a nucleotide sequence which codes a capsid precursor protein; a nucleotide sequence which codes proteinase, capable of splitting the capsid precursor protein; and a control element which controls proteinase expression. Control is carried out such that when the structure is present in a host cell, the control element causes proteinase expression at a level which is sufficient for splitting the capsid precursor protein, but not sufficient for inducing considerable toxicity in the host cell. A vector and a host cell which include said structure are also described, as well as use thereof to generate empty viral capsids.
EFFECT: disclosed is a structure which, during expression in a host cell, is capable of producing empty viral capsids.
19 cl, 12 dwg, 15 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABILISED FMDV CAPSIDS | 2014 |
|
RU2663004C2 |
| FMDV VACCINES BASED ON A RECOMBINANT ADENOVIRAL VECTOR AND USE THEREOF | 2017 |
|
RU2725495C2 |
| OBTAINING PICORNAVIRUS-LIKE PARTICLES IN PLANTS | 2013 |
|
RU2693431C2 |
| RECOMBINANT VIRUS CAPABLE OF STABLE EXPRESSION OF TARGET PROTEINS | 2019 |
|
RU2816428C2 |
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| FMDV-E2 FUSION PROTEINS AND USE THEREOF | 2016 |
|
RU2714428C2 |
| POLYEPITOPE PROTEIN COMPOSITION FOR INDUCING IMMUNE RESPONSE AGAINST FOOT-AND-MOUTH DISEASE VIRUS | 2010 |
|
RU2453557C1 |
| METHOD FOR INDIRECTLY DETERMINING THE TITER OF THE INFECTIOUS ACTIVITY OF FMDV IN NON-INACTIVATED RAW MATERIALS FOR VACCINES USING A MATHEMATICAL DOUBLE DIFFERENTIAL OF THE CROSSING POINT DATA DURING AMPLIFICATION OF VIRAL CDNA | 2022 |
|
RU2793900C1 |
| POLYEPITOPE PROTEIN, NUCLEOTIDE SEQUENCE CODING POLYEPITOPE PROTEIN, PLASMID WITH SEQUENCE CODING POLYEPITOPE PROTEIN, AND PREPARATION OF POLYEPITOPE PROTEIN FOR INDUCTION OF IMMUNE RESPONSE ON MURRAIN VIRUS | 2010 |
|
RU2467014C2 |
| RECOMBINANT ADEN-ASSOCIATED VIRUS, WHICH IS HYBRID OF AAV9 AND AAVrh74 SEROTYPES, WITH REDUCED TROPISM FOR LIVER TISSUE | 2019 |
|
RU2812279C2 |
